These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 7614468)

  • 41. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
    Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
    J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
    McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
    Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    Gutierrez MC; Detre S; Johnston S; Mohsin SK; Shou J; Allred DC; Schiff R; Osborne CK; Dowsett M
    J Clin Oncol; 2005 Apr; 23(11):2469-76. PubMed ID: 15753463
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
    Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
    Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.
    Drury SC; Detre S; Leary A; Salter J; Reis-Filho J; Barbashina V; Marchio C; Lopez-Knowles E; Ghazoui Z; Habben K; Arbogast S; Johnston S; Dowsett M
    Endocr Relat Cancer; 2011 Oct; 18(5):565-77. PubMed ID: 21734071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors.
    Zhang QX; Hilsenbeck SG; Fuqua SA; Borg A
    J Steroid Biochem Mol Biol; 1996 Nov; 59(3-4):251-60. PubMed ID: 9010317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ki-67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D.
    Henzen-Logmans SC; Fieret EJ; Berns EM; van der Burg ME; Klijn JG; Foekens JA
    Int J Cancer; 1994 May; 57(4):468-72. PubMed ID: 8181851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of tamoxifen on pS2 expression in human breast cancers.
    Motomura K; Koyama H; Noguchi S; Inaji H; Kasugai T
    Oncology; 1997; 54(5):424-8. PubMed ID: 9260605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Expression of pS2-protein in breast cancer].
    Kawabata K; Watanabe K; Ozaki S
    Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of the pS2 protein and correlation with estrogen receptor status in fine-needle aspirates from breast carcinomas.
    Sauer T; Naess O
    Diagn Cytopathol; 1994; 11(2):165-7. PubMed ID: 7813365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast.
    Paone JF; Abeloff MD; Ettinger DS; Arnold EA; Baker RR
    Surg Gynecol Obstet; 1981 Jan; 152(1):70-4. PubMed ID: 7455895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
    Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
    Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
    Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
    Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies.
    Chebil G; Bendahl PO; Idvall I; Fernö M
    Acta Oncol; 2003; 42(7):719-25. PubMed ID: 14690157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumor cell lines derived following exposure to antitumor drugs or to fractionated X-irradiation.
    Whelan RD; Hill BT
    Breast Cancer Res Treat; 1993; 26(1):23-39. PubMed ID: 8400321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen--especially for progesterone receptor positive tumors with a high proliferation.
    Fernö M; Baldetorp B; Bendahl PO; Borg A; Ewers SB; Olsson H; Rydén S; Sigurdsson H; Killander D
    Breast Cancer Res Treat; 1995; 36(1):23-34. PubMed ID: 7579503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.